Hurley Capital’s Cardiff Oncology CRDF Stock Holding History

Hurley Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,100	Closed	-$3.4K	–	685
2026 Q1	$3.4K	Sell	2,100 -5,000	-70%	-$10.3K	﹤0.01%	510
2025 Q4	$20K	Hold	7,100	–	–	0.01%	256
2025 Q3	$14.6K	Buy	+7,100	New	+$19.6K	0.01%	318

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Hurley Capital's CRDF Position: Q2 2026 in Review

Hurley Capital sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 2,100 shares — an estimated $3.4K sold.

Hurley Capital first reported a position in CRDF in Q3 2025 and held it in 3 quarters. The position peaked at $20K in Q4 2025. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Hurley Capital reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
Hurley Capital sold 2,100 Cardiff Oncology shares in Q2 2026, an estimated $3.4K.
Hurley Capital first reported a position in Cardiff Oncology in Q3 2025 and held it in 3 quarters.
Hurley Capital's Cardiff Oncology position peaked at $20K in Q4 2025.
104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.